DECISION OF THE EEA JOINT COMMITTEE No 134/2026

of 30 April 2026

amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2026/1488]

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof,

Whereas:

(1) Commission Implementing Regulation (EU) 2026/312 of 10 February 2026 renewing the approval of the active substance maltodextrin as a low-risk active substance in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulation (EU) No 540/2011 ( 1 ) is to be incorporated into the EEA Agreement.

(2) Commission Implementing Regulation (EU) 2026/321 of 12 February 2026 amending Implementing Regulations (EU) 2017/1506 and (EU) No 540/2011 as regards the conditions of approval of the active substance maleic hydrazide ( 2 ) is to be incorporated into the EEA Agreement.

(3) Commission Implementing Regulation (EU) 2026/372 of 20 February 2026 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1-decanol, 1-naphthylacetamide, 1-naphthylacetic acid, 6-benzyladenine, aluminium sulfate, boscalid, dodine, esfenvalerate, eugenol, fenpyroximate, fluazifop-P, fluazinam, fluometuron, fluopyram, flutolanil, geraniol, malathion, penoxsulam, pinoxaden, prohexadione, proquinazid, prosulfuron, pyrethrins, pyridaben, pyrimethanil, sintofen, spiroxamine, sulphur and thymol ( 3 ) is to be incorporated into the EEA Agreement.

(4) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

Chapter XV of Annex II to the EEA Agreement is amended as follows:

The following indents are added in point 13a (Commission Implementing Regulation (EU) No 540/2011):

‘—

32026 R 0312 : Commission Implementing Regulation (EU) 2026/312 of 10 February 2026 ( OJ L, 2026/312, 11.2.2026 ),

— 32026 R 0321 : Commission Implementing Regulation (EU) 2026/321 of 12 February 2026 ( OJ L, 2026/321, 13.2.2026 ),

— 32026 R 0372 : Commission Implementing Regulation (EU) 2026/372 of 20 February 2026 ( OJ L, 2026/372, 23.2.2026 ).’

The following is added in point 13zzzzzzzy (Commission Implementing Regulation (EU) 2017/1506):

‘, as amended by:

— 32026 R 0321 : Commission Implementing Regulation (EU) 2026/321 of 12 February 2026 ( OJ L, 2026/321, 13.2.2026 ).’

The following point is inserted after point 13zzzzzzzzzzzzzzzq (Commission Implementing Regulation (EU) 2025/2313):

‘13zzzzzzzzzzzzzzzr.

32026 R 0312 : Commission Implementing Regulation (EU) 2026/312 of 10 February 2026 renewing the approval of the active substance maltodextrin as a low-risk active substance in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulation (EU) No 540/2011 ( OJ L, 2026/312, 11.2.2026 ).’

Article 2

The texts of Implementing Regulations (EU) 2026/312, (EU) 2026/321 and (EU) 2026/372 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union , shall be authentic.

Article 3

This Decision shall enter into force on 1 May 2026, provided that all the notifications under Article 103(1) of the EEA Agreement have been made ( *1 ) .

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union .

Done at Brussels, 30 April 2026.

For the EEA Joint Committee

The President

Nicolas VON LINGEN

( 1 ) OJ L, 2026/312, 11.2.2026, ELI: http://data.europa.eu/eli/reg_impl/2026/312/oj .

( 2 ) OJ L, 2026/321, 13.2.2026, ELI: http://data.europa.eu/eli/reg_impl/2026/321/oj .

( 3 ) OJ L, 2026/372, 23.2.2026, ELI: http://data.europa.eu/eli/reg_impl/2026/372/oj .

( *1 ) No constitutional requirements indicated.

ELI: http://data.europa.eu/eli/dec/2026/1488/oj

ISSN 1977-0677 (electronic edition)